癌胚抗原
抗体-药物偶联物
癌症
医学
抗体
癌症研究
抗原
人口
药理学
肿瘤抗原
免疫学
免疫疗法
单克隆抗体
内科学
环境卫生
肿瘤相关抗原
作者
Puja Sapra,Marc Isaac Damelin,John F. DiJoseph,Kimberly Marquette,Kenneth G. Geles,Jonathon Golas,Maureen M. Dougher,Bitha Narayanan,Andreas Giannakou,Kiran M. Khandke,Russell G. Dushin,Elana Ernstoff,Judy Lucas,Mauricio Leal,George Hu,Christopher J. O’Donnell,Lioudmila Tchistiakova,Robert T. Abraham,Hans‐Peter Gerber
标识
DOI:10.1158/1535-7163.mct-12-0603
摘要
Antibody-drug conjugates (ADC) represent a promising therapeutic modality for the clinical management of cancer. We sought to develop a novel ADC that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells (TIC), which comprise the most aggressive cell population in the tumor. We optimized an anti-5T4 ADC (A1mcMMAF) by sulfydryl-based conjugation of the humanized A1 antibody to the tubulin inhibitor monomethylauristatin F (MMAF) via a maleimidocaproyl linker. A1mcMMAF exhibited potent in vivo antitumor activity in a variety of tumor models and induced long-term regressions for up to 100 days after the last dose. Strikingly, animals showed pathologic complete response in each model with doses as low as 3 mg antibody/kg dosed every 4 days. In a non-small cell lung cancer patient-derived xenograft model, in which 5T4 is preferentially expressed on the less differentiated tumor cells, A1mcMMAF treatment resulted in sustained tumor regressions and reduced TIC frequency. These results highlight the potential of ADCs that target the most aggressive cell populations within tumors, such as TICs. In exploratory safety studies, A1mcMMAF exhibited no overt toxicities when administered to cynomolgus monkeys at doses up to 10 mg antibody/kg/cycle × 2 and displayed a half-life of 5 days. The preclinical efficacy and safety data established a promising therapeutic index that supports clinical testing of A1mcMMAF.
科研通智能强力驱动
Strongly Powered by AbleSci AI